Facilities

Our Tiigi facility, located at Tartu Biotechnology Park (Tiigi tn 61b, 50410 Tartu, Estonia), serves as TBD Pharmatech’s central hub for research and development, analytical quality control, and small-scale GMP manufacturing activities. The facility integrates approximately 1000 m² of GMP-certified laboratories and production areas, accommodating early-phase API development, scale-up processes, and clinical batch manufacturing. Alongside corporate offices and administrative functions, Tiigi features eight dedicated cGMP-qualified production rooms capable of batch sizes ranging from milligram to 150 liters.

Our RnD and analytics laboratories provide comprehensive capabilities, including model and high-pressure reactors for process optimization, sophisticated preparative chromatography techniques (Flash chromatography, Prep-HPLC), vacuum-based systems for evaporation and drying, and extensive analytical instrumentation such as HPLC systems (with DAD and CAD detection), HPLC-MS, GC (including GC-HS), Karl Fischer titration, polarimetry, viscosimetry, and automatic titration methods.

In addition, Tiigi hosts specialized pilot and small-scale GMP manufacturing equipment, featuring glass-lined and jacketed glass reactors up to 150 liters, heating-cooling circulators operating from -40°C to +200°C, batch centrifuges for solid-liquid separation, vacuum-assisted Nutsche filters, tray dryers (vacuum and circulating air), hammer mills for particle-size control,
and Class D clean areas for final API processing and packaging. This fully integrated environment ensures seamless progression of client projects from concept through clinical phases.

Our new Välja facility—scheduled to be fully operational and GMP-licensed by the end of 2025 —is strategically located at Välja tee 4a, Soinaste, 61709, Tartu maakond. This dedicated plant features over 3000 m² of production space built to GMP standards, with substantial room for future expansion. Välja ensures stability and security for your EU-based pharmaceutical supply chains.

The facility’s advanced chemical synthesis capabilities include reactors ranging from 50 L to 1000 L, capable of accommodating a diverse range of small-molecule synthesis projects. Precision-controlled temperature systems complement these reactors, providing reliable process conditions to ensure consistent, high-quality results. Integrated purification technologies —including advanced filtration (Nutsche filters, stainless steel filter reactors), high-performance centrifugation, and comprehensive drying systems (vacuum tray dryers, drying ovens)— guarantee the effective isolation and purification of APIs.

The facility will house 10 GMP production rooms when fully qualified at maximal capcity, specifically engineered for flexibility and scalability, Välja offers an adaptable manufacturing environment tailored to meet diverse client needs. This strategic investment enhances our ability to serve as a trusted, reliable partner in pharmaceutical manufacturing, effectively meeting the evolving demands of the global marketplace.